Lydia W. S. Finley | |
---|---|
Awards | Searle Scholar |
Scientific career | |
Fields | Metabolism, Stem Cell Biology |
Institutions | Memorial Sloan Kettering |
Doctoral advisor | Marcia Haigis |
Other academic advisors | Craig Thompson |
Website | https://www.mskcc.org/research/ski/labs/lydia-finley |
Lydia W. S. Finley is an American scientist and an assistant member at the Cell Biology Program at Memorial Sloan Kettering Cancer Center and an assistant professor at Weill Cornell Medical College. Finley is known for her contributions to understanding the metabolic underpinnings of stem cell fate.
Finley received her Bachelor of Science (BS) degree summa cum laude from Yale University. Finley completed her PhD at Harvard Medical School, where she worked in the laboratory of Marcia Haigis. Finley then worked as a postdoctoral fellow in the laboratory of Craig Thompson at Memorial Sloan Kettering Cancer Center. After completing her postdoctoral work, Finley opened her own laboratory in 2017, which is located in the Memorial Sloan Kettering Cancer Center. [1] [2] [3]
Finley has received various awards for her work. These include the Dale F. Frey Award for Breakthrough Scientists from the Damon Runyon Cancer Research Foundation and the Searle Scholars Award. Finley currently serves as an associate editor for Cancer & Metabolism [4] and a reviewing editor at eLife. [5] As of April 2022, Finley has authored over 40 publications and has an h-index of 30. [6]
Finley's research has focused on interrogating the connections between metabolites and their role in regulating embryonic stem cell self-renewal and cell fate decisions. Notably, as a postdoctoral fellow, Finley and Bryce W. Carey discovered that intracellular α-ketoglutarate levels regulated chromatin and gene expression, and contributes to embryonic stem cell renewal. [3] [7] In 2022, Finley and co-authors published a paper describing a non-canonical arm of the TCA cycle. [8] [9] [10] [11]
In multicellular organisms, stem cells are undifferentiated or partially differentiated cells that can change into various types of cells and proliferate indefinitely to produce more of the same stem cell. They are the earliest type of cell in a cell lineage. They are found in both embryonic and adult organisms, but they have slightly different properties in each. They are usually distinguished from progenitor cells, which cannot divide indefinitely, and precursor or blast cells, which are usually committed to differentiating into one cell type.
Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the inner cell mass (embryoblast) using immunosurgery results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage have the same moral considerations as embryos in the post-implantation stage of development.
Oct-4, also known as POU5F1, is a protein that in humans is encoded by the POU5F1 gene. Oct-4 is a homeodomain transcription factor of the POU family. It is critically involved in the self-renewal of undifferentiated embryonic stem cells. As such, it is frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely regulated; too much or too little will cause differentiation of the cells.
Homeobox protein NANOG(hNanog) is a transcriptional factor that helps embryonic stem cells (ESCs) maintain pluripotency by suppressing cell determination factors. hNanog is encoded in humans by the NANOG gene. Several types of cancer are associated with NANOG.
Induced pluripotent stem cells are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered by Shinya Yamanaka and Kazutoshi Takahashi in Kyoto, Japan, who together showed in 2006 that the introduction of four specific genes, collectively known as Yamanaka factors, encoding transcription factors could convert somatic cells into pluripotent stem cells. Shinya Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent."
SRY -box 2, also known as SOX2, is a transcription factor that is essential for maintaining self-renewal, or pluripotency, of undifferentiated embryonic stem cells. Sox2 has a critical role in maintenance of embryonic and neural stem cells.
Shinya Yamanaka is a Japanese stem cell researcher and a Nobel Prize laureate. He is a professor and the director emeritus of Center for iPS Cell Research and Application, Kyoto University; as a senior investigator at the UCSF-affiliated Gladstone Institutes in San Francisco, California; and as a professor of anatomy at University of California, San Francisco (UCSF). Yamanaka is also a past president of the International Society for Stem Cell Research (ISSCR).
Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.
Diane L. Barber is an American cell biologist. She is an Endowed Professor and Chair of the Department of Cell and Tissue Biology at University of California, San Francisco (UCSF) and an elected American Association for the Advancement of Science fellow in recognition of her "distinguished contributions on cell signaling by plasma membrane ion transport proteins and on the design and function of proteins regulated by intracellular pH dynamics." In addition to teaching graduate and professional students and her administrative service, she directs a research laboratory funded by grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF).
Marcel R.M. van den Brink is a Dutch oncologist and researcher known for his research in hematopoietic stem cell transplantation for cancer patients.
Lorenz Studer is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City. He is a developmental biologist and neuroscientist who is pioneering the generation of midbrain dopamine neurons for transplantation and clinical applications. His expertise in cell engineering spans a wide range of cells/tissues within the nervous system geared toward disease modeling and exploring cell replacement therapy. Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a Professor of Neuroscience at Weill Cornell Medical College in New York City, NY.
Jeanne Frances Loring is an American stem cell biologist, developmental neurobiologist, and geneticist. She is the founding Director of the Center for Regenerative Medicine and emeritus professor at the Scripps Research Institute in La Jolla, California. She has founded two biotechnology companies, Arcos BioScience (1999) and Aspen Neuroscience (2018)
Viviane Tabar is an American neurosurgeon, the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York since 2017.
Diana Hargreaves is an American biologist and assistant professor at The Salk Institute for Biological Studies and member of The Salk Cancer Center. Her laboratory focuses on epigenetic regulation by the BAF (SWI/SNF) chromatin remodeling complexes in diverse physiological processes including development, immunity, and diseases such as cancer.
Michel Sadelain is an genetic engineer and cell therapist at Memorial Sloan Kettering Cancer Center, New York, New York, where he holds the Steve and Barbara Friedman Chair. He is the founding director of the Center for Cell Engineering and the head of the Gene Transfer and Gene Expression Laboratory. He is a member of the department of medicine at Memorial Hospital and of the immunology program at the Sloan Kettering Institute. He is best known for his major contributions to T cell engineering and chimeric antigen receptor (CAR) therapy, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer.
Scott Neal Keeney is an American molecular biologist.
Eran Meshorer is an Israeli scientist, professor of epigenetics and stem cells at the Alexander Silberman Institute of Life Sciences, and The Edmond and Lily Safra Center for Brain Sciences, the Hebrew University of Jerusalem. Meshorer is the Arthur Gutterman Chair for Stem Cell Research.
Jeffrey L. Wrana is a Canadian cancer researcher. He is the CIBC Breast Cancer Research Scientist and Mary Janigan Research Chair in Molecular Cancer Therapeutic at Mount Sinai Hospital and University of Toronto. As a Tier 1 Canada Research Chair in Medical Genetics and Microbiology at U of T, Wrana was elected a Fellow of the Royal Society of Canada.
Trevor K. Archer is a Bahamian research scientist who is a National Institutes of Health Distinguished Investigator and deputy director at the National Institute of Environmental Health Sciences. He leads the Chromatin and Gene Expression Group, who investigate chromatin, epigenetics and embryonic stem cells pluripotency.
JacobH. Hanna is a Palestinian Arab-Israeli biologist who is working as a professor in the Department of Molecular Genetics at the Weizmann Institute of Science in Rehovot, Israel. An expert in embryonic stem cell research, he is most recognized for developing the first bona fide synthetic embryo models from stem cells in the petri dish in mice and humans.